Radient Pharmaceuticals Corporation fka RXPC

[Future Doc]

@Gold, Referring to the potential of the J & J test. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/89162?icn=ctc&ici=home-page-feature-box-89162

This is a test very similar to the proposed J & J test. What is the HUGE draw back to a test like this? What leaves the market wide open for a test like Onko-Sure EVEN if the J & J test or a test like this one is fully developed and available? The word metastatic. I'm sure that you understand the implications of this word, Gold. But, for those with a non-science background, the metastatic phase of cancer is when the cancer cells begin to "de-anchor" if you will and spread throughout the body via the blood stream. This is a slightly advanced to advanced stage of cancer. Therefore, a test like the one on the Mayo website or the J&J test would not be remotely effective as an early stage detection tool. That is why a test like Onko-Sure or one similar to Onko-Sure can still thrive in a market that contains these type of "cancer capturing" tests. Not to knock the technology, it is probably an excellent test for identifying and quantifying metastatic cancer cells. But it is only useful when cancer is beginning to circulate, at which point it could be at a stage that is very difficult to treat. Maybe it can be used for pure identification. In this case it would have to be EXTREMELY sensitive to identify at stage I or II. I'll have to look up the average number of metastatic cells in early stage cancer but my guess is that it is very low if even detectable/ present at all. FDP are present and detectable as soon as cancer cells/ tumor begins to develop and grow, which is why it can be used as an early stage detection marker. False positives etc aside, the core technologies in the Onko-Sure and J & J tests are completely different and allow for both to exist at the same time.